A newly published forensic toxicology study from Australia examines the detection of a synthetic opioid known as 2-naphthyl U-47700, or β-U10, in a series of heroin-related deaths in Victoria.
The research appeared online on November 19, 2026, in the Australian Journal of Forensic Sciences. It was authored by Lachlan Scully, Matthew Di Rago, Olaf H. Drummer, Joanna Glengarry, Kerryn Crump, Linda Glowacki and Dimitri Gerostamoulos.
The publication draws attention to the challenges forensic laboratories face when investigating deaths involving mixtures of established illicit drugs and emerging synthetic substances.
β-U10 belongs to a group of synthetic opioids chemically related to U-47700. Unlike fentanyl, it belongs to a different structural family of opioids.
The substance is not entirely new. Earlier Australian research documented its detection in drug-related samples beginning in 2020, while subsequent scientific investigations examined its pharmacological activity.
One earlier study reported seven blood samples containing β-U10, including six collected in October 2020 and one in December 2021. These findings provide historical context but should not automatically be treated as the results of the newly published study.
Forensic toxicologists use analytical techniques to identify drugs and their metabolites in biological specimens collected during investigations.
Methods such as liquid chromatography coupled with tandem mass spectrometry can help laboratories detect and confirm substances that may be difficult to distinguish using less specific screening approaches.
The identification of emerging synthetic opioids is particularly important because routine toxicology panels may not include every newly encountered compound.
However, detecting an opioid in a postmortem sample does not independently establish that the substance caused or contributed to death.
Investigators must consider toxicological concentrations, other substances present, medical and autopsy findings, and the circumstances surrounding the death.
The full experimental results of the November 2026 publication have not yet been independently verified. Its case count, measured concentrations and conclusions about the role of β-U10 in the reported fatalities therefore remain to be confirmed.
The research nevertheless addresses a significant issue in forensic toxicology: the need for analytical laboratories to recognize emerging compounds and distinguish them accurately from chemically related substances.
As synthetic drug markets change, reliable analytical identification and careful interpretation remain essential to understanding drug-related deaths and supporting public health surveillance.